ProCE Banner Activity

First-Generation TRK Inhibitors: Clinical Evidence and Indications

Podcast Episodes
In this podcast episode, listen to an engaging discussion between George D. Demetri, MD, and Alexander Drilon, MD, on key clinical trials leading to FDA approvals of first-generation TRK inhibitors, where these agents fit into treatment paradigms for various solid tumors, and considerations for choosing among currently available TRK inhibitors.

Released: October 15, 2021

Expiration: October 14, 2022

No longer available for credit.

Share

Faculty

George D. Demetri

George D. Demetri, MD

Professor of Medicine
Harvard Medical School
Harvard University
Co-Director, Ludwig Center at Harvard
Senior Vice President for Experimental Therapeutics
Director,
Sarcoma Center
Dana-Farber Cancer Institute
Boston, Massachusetts

Alexander Drilon

Alexander Drilon, MD

Chief, Early Drug Development
Attending, Thoracic
Memorial Sloan Kettering Cancer Center
New York, New York

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by an educational grant from

Bayer Healthcare Pharma

Faculty Disclosure

Primary Author

George D. Demetri, MD

Professor of Medicine
Harvard Medical School
Harvard University
Co-Director, Ludwig Center at Harvard
Senior Vice President for Experimental Therapeutics
Director,
Sarcoma Center
Dana-Farber Cancer Institute
Boston, Massachusetts

George D. Demetri, MD, has disclosed that he has received funds for research support and consulting fees from Bayer, Ignyta, Loxo, and Roche and serves as a member of the board of directors for Blueprint Medicines.

Alexander Drilon, MD

Chief, Early Drug Development
Attending, Thoracic
Memorial Sloan Kettering Cancer Center
New York, New York

Alexander Drilon, MD, has disclosed that he has received honoraria or served on the advisory boards of 14ner/Elevation Oncology, AbbVie, ArcherDX, AstraZeneca, AXIS, BeiGene, BergenBio, Blueprint Medicines, Chugai Pharm, EMD Serono, EPG Health, Exelixis, Harborside, Helsinn, Hengrui, Ignyta/Genentech/Roche, Loxo/Bayer/Lilly, Liberum, Melendi, Merus, Monopteros, MORE Health, Novartis, Nuvalent, Pfizer, Remedica, Repare RX, Takeda/Ariad/Millennium, TP Therapeutics, Tyra Biosciences, and Verastem; has received funding paid to his institution from Exelixis, GlaxoSmithKline, Pfizer, PharmaMar, Teva, and Taiho; has received funds for research support from Foundation Medicine; and has received other financial or material support from Boehringer Ingelheim, Merck, Merus, and Puma.